TAK1-IN-3

CAS No. 494772-87-1

TAK1-IN-3( —— )

Catalog No. M35215 CAS No. 494772-87-1

TAK1-IN-3 is a novel ATP-competitive TAK1 inhibitor for the study of cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 70 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    TAK1-IN-3
  • Note
    Research use only, not for human use.
  • Brief Description
    TAK1-IN-3 is a novel ATP-competitive TAK1 inhibitor for the study of cancer.
  • Description
    TAK1-IN-3 is a potent ATP-competitive TAK1 inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    p38 MAPK
  • Recptor
    MAPK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    494772-87-1
  • Formula Weight
    317.41
  • Molecular Formula
    C16H19N3O2S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (315.05 mM; Ultrasonic )
  • SMILES
    O=C(N)C=1SC(=CC1N)C=2C=CC(=CC2)CN3CCOCC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Kamebakaurine

    Kamebakaurin has the ability to protect the liver from APAP-induced hepatotoxicity, presumably by both inhibiting the inflammatory response and oxidative stress.

  • SSK1

    SSK1 is a compound that selectively kills senescent cells and is a precursor for β-galactosidase, which can reduce the inflammatory response of the body. SSK1 can activate the phosphorylation of p38 MAPK and MKK3/MKK6 in senescent cells, and promote mitochondrial DNA damage in senescent cells.

  • Iroxanadine

    Iroxanadine (BRX-005) is a Novel small molecule MAPK p38 inhibitor that induces phosphorylation of p38 SAPK and induces concentration-dependent relaxation in guinea pig pulmonary artery preparations precontracted with phenylephrine.